Reducing risks to human and animal health from exposure to N-methyl pyrrolidone in veterinary medicines

21. April 2023 – On 8 December 2022, European Medicines Agency’s (EMA) veterinary medicines committee, the CVMP, recommended new measures to reduce the risks from exposure to the excipient N-methyl pyrrolidone (NMP) for women who may handle NMP-containing veterinary medicines (NMP is classified as a substance that can cause birth defects following exposure during pregnancy) and animals that are given these medicines. The recommendations address inconsistencies in the product information of veterinary medicines containing NMP, which are marketed in many European Union (EU) Member States.

For more information, see here.